Hamdi Mbarek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hamdi Mbarek has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
Dorret I. Boomsma
Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
25 shared publications- Eco J. C. de Geus
Department of Biological Psychology, Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
24 shared publications - Gonneke Willemsen
Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
24 shared publications Jouke-Jan Hottenga
Department of Biological Psychology, Netherlands Twin Register, Vrije Universiteit , Amsterdam, The Netherlands
21 shared publications- Dorret I. Boomsma
Vrije Universiteit Amsterdam
16 shared publications - Jaakko Kaprio
University of Helsinki/FIMM
15 shared publications
Latest Publications
- Open Access
Combined genome-wide association studies in humans and cattle: Cross-species genetic insights into dizygotic twinning
To leverage independent genetic evidence from multiple species, we developed a cross-species gene-based GWAS meta-analysis framework and applied this to Dizygotic Twinning (DZT) in humans and cattle. After meta-analysis within species, we converted human and cattle GWAS summary statistics to gene-level association signals within each species, mapped genes across species through human-cattle orthology, and then combined gene-level evidence for orthologous genes across the two species. DZT is defined as giving birth to multiple offspring after a single pregnancy resulting from spontaneous multiple ovulation. In humans, DZT occurs in about 1% of pregnancies with heritability estimates of 20% to 30% whilst in cattle DZT occurs in 1-5% of pregnancies and heritability is estimated at about 11%. Here, we present the largest human GWAS meta-analysis including data from 1,395,285 participants. We identified 16 genetic regions of interest, including 12 independent loci from the SNP based analyses and 4 genes identified in the gene-based MAGMA analyses. Among the prioritized genes are follicle stimulation hormone receptor (FSHR) and growth differentiation factor 9 (GDF9), that both are involved in ovarian folliculogenesis. Cattle GWAS summary statistics were based on data from 2,656 Irish Holstein bulls with estimated breeding values for predisposition to twinning based on 2,238,936 birth records, and 86,391 German Holstein dams. After combining the gene-level analyses for 13,225 genes mapped as orthologous across the human and cattle data we identify FSHR as a central locus for DZT in both humans and cattle. We find evidence of additional associations, including ACVR2A, which plays a role in embryonic implantation and TUFM, which has previously been implicated in premature ovarian insufficiency. Our approach provides a promising framework for future cross-species comparative GWAS studies. It shows benefits for gene discovery and gene prioritization and in our application expands available functional follow-up data, allowing us to leverage cattle eQTL data to resolve human GWAS loci. The method and underlying philosophy presented here are transferable to other shared phenotypes across several species.
Open AccessCombined genome-wide association studies in humans and cattle: Cross-species genetic insights into dizygotic twinning
To leverage independent genetic evidence from multiple species, we developed a cross-species gene-based GWAS meta-analysis framework and applied this to Dizygotic Twinning (DZT) in humans and cattle. After meta-analysis within species, we converted human and cattle GWAS summary statistics to gene-level association signals within each species, mapped genes across species through human-cattle orthology, and then combined gene-level evidence for orthologous genes across the two species. DZT is defined as giving birth to multiple offspring after a single pregnancy resulting from spontaneous multiple ovulation. In humans, DZT occurs in about 1% of pregnancies with heritability estimates of 20% to 30% whilst in cattle DZT occurs in 1-5% of pregnancies and heritability is estimated at about 11%. Here, we present the largest human GWAS meta-analysis including data from 1,395,285 participants. We identified 16 genetic regions of interest, including 12 independent loci from the SNP based analyses and 4 genes identified in the gene-based MAGMA analyses. Among the prioritized genes are follicle stimulation hormone receptor (FSHR) and growth differentiation factor 9 (GDF9), that both are involved in ovarian folliculogenesis. Cattle GWAS summary statistics were based on data from 2,656 Irish Holstein bulls with estimated breeding values for predisposition to twinning based on 2,238,936 birth records, and 86,391 German Holstein dams. After combining the gene-level analyses for 13,225 genes mapped as orthologous across the human and cattle data we identify FSHR as a central locus for DZT in both humans and cattle. We find evidence of additional associations, including ACVR2A, which plays a role in embryonic implantation and TUFM, which has previously been implicated in premature ovarian insufficiency. Our approach provides a promising framework for future cross-species comparative GWAS studies. It shows benefits for gene discovery and gene prioritization and in our application expands available functional follow-up data, allowing us to leverage cattle eQTL data to resolve human GWAS loci. The method and underlying philosophy presented here are transferable to other shared phenotypes across several species.
- 31 July 2026
- Published by Springer Nature in Nature Reviews Genetics
- Vol. 27 (11) , 816-817
Towards quantifying immune diversity through HLA genomics
- 31 July 2026
- Published by Springer Nature in Nature Reviews Genetics
- Vol. 27 (11) , 816-817
Towards quantifying immune diversity through HLA genomics
- Open Access
Quantifying the contribution of genetic variation to healthcare expenditure across diverse healthcare systems
Healthcare systems must balance rising costs with the delivery of effective care, yet the factors underlying large inter-individual differences in healthcare expenditure remain incompletely understood. Here we examine how genome-wide genetic variation contributes to healthcare costs, analysing inpatient, outpatient, primary care and prescription drug expenditure in up to 1,429,889 individuals from 11 studies across 7 countries. We identify hundreds of common genetic variants robustly associated with healthcare costs, revealing a reproducible polygenic architecture shared across healthcare systems. Individual common variants have modest effects, typically altering annual costs by ∼1-2% per allele, with the strongest signals arising from the HLA region, consistent with pleiotropic effects across autoimmune and inflammatory diseases. In contrast, putative loss-of-function (pLOF) variants (ClinVar/ENIGMA pathogenic variants or LOFTEE high-confidence pLOF) in clinically actionable genes, studied in UK Biobank, have large individual-level consequences: carriers of such variants in BRCA1, BRCA2, MSH2 and APC experience more than a two-fold increase in annual inpatient costs. Cost-associated signals colocalize extensively with autoimmune disorders, cardiometabolic risk factors, pain sensitivity, and depression amongst others. Polygenic scores derived for healthcare costs can predict up to 1.4% of drug-related healthcare expenditure in independent cohorts and retain their effects in within-family analyses, indicating largely direct genetic influences. By linking genetic risk to healthcare expenditure, this work provides a foundation for integrating human genetics into health economics, preventive strategies and population-level screening.
Open AccessQuantifying the contribution of genetic variation to healthcare expenditure across diverse healthcare systems
Healthcare systems must balance rising costs with the delivery of effective care, yet the factors underlying large inter-individual differences in healthcare expenditure remain incompletely understood. Here we examine how genome-wide genetic variation contributes to healthcare costs, analysing inpatient, outpatient, primary care and prescription drug expenditure in up to 1,429,889 individuals from 11 studies across 7 countries. We identify hundreds of common genetic variants robustly associated with healthcare costs, revealing a reproducible polygenic architecture shared across healthcare systems. Individual common variants have modest effects, typically altering annual costs by ∼1-2% per allele, with the strongest signals arising from the HLA region, consistent with pleiotropic effects across autoimmune and inflammatory diseases. In contrast, putative loss-of-function (pLOF) variants (ClinVar/ENIGMA pathogenic variants or LOFTEE high-confidence pLOF) in clinically actionable genes, studied in UK Biobank, have large individual-level consequences: carriers of such variants in BRCA1, BRCA2, MSH2 and APC experience more than a two-fold increase in annual inpatient costs. Cost-associated signals colocalize extensively with autoimmune disorders, cardiometabolic risk factors, pain sensitivity, and depression amongst others. Polygenic scores derived for healthcare costs can predict up to 1.4% of drug-related healthcare expenditure in independent cohorts and retain their effects in within-family analyses, indicating largely direct genetic influences. By linking genetic risk to healthcare expenditure, this work provides a foundation for integrating human genetics into health economics, preventive strategies and population-level screening.
- 30 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Etude des facteurs génétiques de susceptibilité à la polyarthrite rhumathoïde
La polyarthrite rhumatoïde, le rhumatisme inflammatoire chronique le plus fréquent, est une maladie multifactorielle faisant intervenir des facteurs génétiques et environnementaux. Depuis 1978, l’implication du gène HLA-DRB1 est connue, puis en 2005 celle du gène PTPN22, impliqués dans plusieurs autres maladies auto-immunes. Ces deux gènes n’expliquent qu’une partie de la composante génétique de la PR. Ces deux dernières années ont connu une augmentation considérable du nombre des gènes associés à la PR grâce aux études pangénomiques mais les résultats des études publiées sont souvent controversés. Les objectifs de ma thèse sont donc 1) l’étude, par une approche familiale dans la population française en particulier et européenne en général, des nouvelles hypothèses d’association de nouveaux gènes émanant de ces études pangénomiques; 2) la recherche d’autres facteurs génétiques de prédisposition à la PR à l’aide d’une stratégie fondée sur le reséquençage systématique de régions d’intérêts et de gènes candidats. Mon travail de thèse a ciblé, dans un premier temps, les facteurs génétiques fortement suggérés : STAT4, TRAF1/C5, 6q23/TNFAIP3, REL et BLK. D’autres loci ont été aussi étudiés dans le cadre d’une grande étude européenne cas-témoins, tels que : AFF3, KIF5A, CD40, IL2/IL21, CTLA4, CD226, CCL21, CD226, PRKCQ, IL2RA et IL2RB. Parallèlement, l’étude de 20 gènes candidats ainsi que du locus PADI a été entreprise par reséquençage. Ces travaux ont permis d’apporter la confirmation définitive par linkage de la région 6q23/TNFAIP3 comme nouveau facteur génétique de la PR. Un premier argument de liaison a été obtenu pour le gène STAT4, ainsi qu’une suggestion de liaison pour les gènes REL et BLK. Par ailleurs, une réplication de l’association avec le gène AFF3 a été obtenue par la grande étude cas-contrôle européenne. Enfin, le reséquençage a permis de découvrir de nouveaux variants alléliques, qui sont utilisés pour rechercher de nouveaux facteurs de la PR. En conclusion, mon travail a contribué à l’identification de facteurs génétiques de la PR, qui conduira à une meilleure compréhension des mécanismes moléculaires impliqués dans la pathogenèse de cette maladie, jusqu’à permettre le développement de nouvelles thérapeutiques visant à guérir définitivement la PR.
- 30 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Etude des facteurs génétiques de susceptibilité à la polyarthrite rhumathoïde
La polyarthrite rhumatoïde, le rhumatisme inflammatoire chronique le plus fréquent, est une maladie multifactorielle faisant intervenir des facteurs génétiques et environnementaux. Depuis 1978, l’implication du gène HLA-DRB1 est connue, puis en 2005 celle du gène PTPN22, impliqués dans plusieurs autres maladies auto-immunes. Ces deux gènes n’expliquent qu’une partie de la composante génétique de la PR. Ces deux dernières années ont connu une augmentation considérable du nombre des gènes associés à la PR grâce aux études pangénomiques mais les résultats des études publiées sont souvent controversés. Les objectifs de ma thèse sont donc 1) l’étude, par une approche familiale dans la population française en particulier et européenne en général, des nouvelles hypothèses d’association de nouveaux gènes émanant de ces études pangénomiques; 2) la recherche d’autres facteurs génétiques de prédisposition à la PR à l’aide d’une stratégie fondée sur le reséquençage systématique de régions d’intérêts et de gènes candidats. Mon travail de thèse a ciblé, dans un premier temps, les facteurs génétiques fortement suggérés : STAT4, TRAF1/C5, 6q23/TNFAIP3, REL et BLK. D’autres loci ont été aussi étudiés dans le cadre d’une grande étude européenne cas-témoins, tels que : AFF3, KIF5A, CD40, IL2/IL21, CTLA4, CD226, CCL21, CD226, PRKCQ, IL2RA et IL2RB. Parallèlement, l’étude de 20 gènes candidats ainsi que du locus PADI a été entreprise par reséquençage. Ces travaux ont permis d’apporter la confirmation définitive par linkage de la région 6q23/TNFAIP3 comme nouveau facteur génétique de la PR. Un premier argument de liaison a été obtenu pour le gène STAT4, ainsi qu’une suggestion de liaison pour les gènes REL et BLK. Par ailleurs, une réplication de l’association avec le gène AFF3 a été obtenue par la grande étude cas-contrôle européenne. Enfin, le reséquençage a permis de découvrir de nouveaux variants alléliques, qui sont utilisés pour rechercher de nouveaux facteurs de la PR. En conclusion, mon travail a contribué à l’identification de facteurs génétiques de la PR, qui conduira à une meilleure compréhension des mécanismes moléculaires impliqués dans la pathogenèse de cette maladie, jusqu’à permettre le développement de nouvelles thérapeutiques visant à guérir définitivement la PR.
- Open Access
Impact of Somatic Gene Mutations on Prognosis Prediction in De Novo AML: Unraveling Insights from a Systematic Review and Meta-Analysis
Background: Wide application of genome sequencing technologies has highlighted extensive genetic diversity in Acute Myeloid Leukemia (AML), yet the specific roles of individual genes remain unclear. This systematic review and meta-analysis aims to provide robust evidence for the prognostic impact of somatic gene mutations in de novo AML patients, while also exploring the prevalence of these mutations. Methods: Eligible studies were identified from PubMed and Scopus, with a focus on those reporting the prognostic influence of somatic gene mutations on overall survival (OS) or relapse-free survival (RFS) when compared to wild-type carriers. We calculated the pooled prevalence with 95% confidence intervals to assess the frequency of these mutations, and the pooled Hazard Ratio (HR) to compare OS and RFS associated with specific gene mutations. Results: We evaluated 53 somatic gene mutations using 80 studies, involving 20,048 de novo AML patients. The analysis revealed that the most prevalent affected genes were NPM1 (27%), DNMT3A (26%), and FLT3-ITD (24%). Mutations in CSF3R, TET2, and TP53 were significantly associated with poorer OS or RFS (p < 0.05). Sensitivity analysis confirmed that ASXL1, DNMT3A, and RUNX1 mutations were consistently linked to inferior OS or RFS. In contrast, CEBPAdm mutations were associated with favorable OS [HR = 0.39 (0.30–0.50)] and RFS [HR = 0.44 (0.37–0.54)]. Subgroup analysis showed that FLT3-ITD mutations were consistently associated with worse OS or RFS across all subgroups, though no significant subgroup differences were noted. No significant impact on OS or RFS was observed for mutations in GATA2, FLT3-TKD, KRAS, NRAS, IDH1, and IDH2. Conclusions: These findings provide critical insights into AML prognosis, aiding clinical decision-making and improving risk stratification strategies.
Open AccessImpact of Somatic Gene Mutations on Prognosis Prediction in De Novo AML: Unraveling Insights from a Systematic Review and Meta-Analysis
Background: Wide application of genome sequencing technologies has highlighted extensive genetic diversity in Acute Myeloid Leukemia (AML), yet the specific roles of individual genes remain unclear. This systematic review and meta-analysis aims to provide robust evidence for the prognostic impact of somatic gene mutations in de novo AML patients, while also exploring the prevalence of these mutations. Methods: Eligible studies were identified from PubMed and Scopus, with a focus on those reporting the prognostic influence of somatic gene mutations on overall survival (OS) or relapse-free survival (RFS) when compared to wild-type carriers. We calculated the pooled prevalence with 95% confidence intervals to assess the frequency of these mutations, and the pooled Hazard Ratio (HR) to compare OS and RFS associated with specific gene mutations. Results: We evaluated 53 somatic gene mutations using 80 studies, involving 20,048 de novo AML patients. The analysis revealed that the most prevalent affected genes were NPM1 (27%), DNMT3A (26%), and FLT3-ITD (24%). Mutations in CSF3R, TET2, and TP53 were significantly associated with poorer OS or RFS (p < 0.05). Sensitivity analysis confirmed that ASXL1, DNMT3A, and RUNX1 mutations were consistently linked to inferior OS or RFS. In contrast, CEBPAdm mutations were associated with favorable OS [HR = 0.39 (0.30–0.50)] and RFS [HR = 0.44 (0.37–0.54)]. Subgroup analysis showed that FLT3-ITD mutations were consistently associated with worse OS or RFS across all subgroups, though no significant subgroup differences were noted. No significant impact on OS or RFS was observed for mutations in GATA2, FLT3-TKD, KRAS, NRAS, IDH1, and IDH2. Conclusions: These findings provide critical insights into AML prognosis, aiding clinical decision-making and improving risk stratification strategies.
- Top Cited PapersOpen Access
- 18 April 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (7) , 2269-2276
Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery
Obesity is a major public health challenge. Glucagon-like peptide-1 receptor agonists (GLP1-RA) and bariatric surgery (BS) are effective weight loss interventions; however, the genetic factors influencing treatment response remain largely unexplored. Moreover, most previous studies have focused on race and ethnicity rather than genetic ancestry. Here we analyzed 10,960 individuals from 9 multiancestry biobank studies across 6 countries to assess the impact of known genetic factors on weight loss. Between 6 and 12 months, GLP1-RA users had an average weight change of −3.93% or −6.00%, depending on the outcome definition, with modest ancestry-based differences. BS patients experienced −21.17% weight change between 6 and 48 months. We found no significant associations between GLP1-RA-induced weight loss and polygenic scores for body mass index or type 2 diabetes, nor with missense variants in GLP1R. A higher body mass index polygenic score was modestly linked to lower weight loss after BS (+0.7% per s.d., P = 1.24 × 10−4), but the effect attenuated in sensitivity analyses. Our findings suggest known genetic factors have limited impact on GLP1-RA effectiveness with respect to weight change and confirm treatment efficacy across ancestry groups.
- 18 April 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (7) , 2269-2276
Top Cited PapersOpen AccessAssociation between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery
Obesity is a major public health challenge. Glucagon-like peptide-1 receptor agonists (GLP1-RA) and bariatric surgery (BS) are effective weight loss interventions; however, the genetic factors influencing treatment response remain largely unexplored. Moreover, most previous studies have focused on race and ethnicity rather than genetic ancestry. Here we analyzed 10,960 individuals from 9 multiancestry biobank studies across 6 countries to assess the impact of known genetic factors on weight loss. Between 6 and 12 months, GLP1-RA users had an average weight change of −3.93% or −6.00%, depending on the outcome definition, with modest ancestry-based differences. BS patients experienced −21.17% weight change between 6 and 48 months. We found no significant associations between GLP1-RA-induced weight loss and polygenic scores for body mass index or type 2 diabetes, nor with missense variants in GLP1R. A higher body mass index polygenic score was modestly linked to lower weight loss after BS (+0.7% per s.d., P = 1.24 × 10−4), but the effect attenuated in sensitivity analyses. Our findings suggest known genetic factors have limited impact on GLP1-RA effectiveness with respect to weight change and confirm treatment efficacy across ancestry groups.
- Open Access
Understanding Heritable Variation Among Hosts in Infectious Diseases Through the Lens of Twin Studies
Genetic factors have been hypothesized to contribute to the heterogeneity in the response to infectious diseases (IDs). The classical twin design provides a powerful tool to estimate the role of genetic contributions to variation in infection outcomes. With this design, the impact of heritability on the proneness as well as infection- and vaccine-induced immune responses have been documented for multiple infections, including tuberculosis, malaria, leprosy, otitis media, polio, mumps, measles, rubella, influenza, hepatitis B, and human papillomavirus infections, and recently, SARS-CoV-2. The current data show the heritable aspect in nearly all infections considered. In this contribution, we review and discuss human twin studies on the heritability of host characteristics in liability and response to IDs. This review emphasizes the importance of considering factors such as sex, disease stages, and disease presentation when assessing heritability and argues that the classical twin design provides a unique circumstance for exploring the genetic contribution as twins share levels of maternal antibodies, ancestral background, often the dates and number of vaccine doses, differences in vaccines’ manufacturing and storage, age, family environment, and other exposures. Additionally, we highlight the value of twin studies and the usefulness of combining the twin model with contemporary genomics technologies and advanced statistical tools to grasp a comprehensive and nuanced understanding of heritability in IDs.
Open AccessUnderstanding Heritable Variation Among Hosts in Infectious Diseases Through the Lens of Twin Studies
Genetic factors have been hypothesized to contribute to the heterogeneity in the response to infectious diseases (IDs). The classical twin design provides a powerful tool to estimate the role of genetic contributions to variation in infection outcomes. With this design, the impact of heritability on the proneness as well as infection- and vaccine-induced immune responses have been documented for multiple infections, including tuberculosis, malaria, leprosy, otitis media, polio, mumps, measles, rubella, influenza, hepatitis B, and human papillomavirus infections, and recently, SARS-CoV-2. The current data show the heritable aspect in nearly all infections considered. In this contribution, we review and discuss human twin studies on the heritability of host characteristics in liability and response to IDs. This review emphasizes the importance of considering factors such as sex, disease stages, and disease presentation when assessing heritability and argues that the classical twin design provides a unique circumstance for exploring the genetic contribution as twins share levels of maternal antibodies, ancestral background, often the dates and number of vaccine doses, differences in vaccines’ manufacturing and storage, age, family environment, and other exposures. Additionally, we highlight the value of twin studies and the usefulness of combining the twin model with contemporary genomics technologies and advanced statistical tools to grasp a comprehensive and nuanced understanding of heritability in IDs.
- Open Access
Polygenic Scores for Dizygotic Twinning: Insights into the Genetic Architecture of Female Fertility
Natural dizygotic twinning (DZT) results from hyper-ovulation and is considered an indicator of female fertility. DZT has low polygenicity, with only 0.20% of SNPs estimated to have a nonzero effect. A polygenic score (PGS) for DZT explains 1.6% of variance in DZT liability and we observe an odds ratio of 2.29 between the 1 st and the 10 th PGS decile. The PGS is higher in mothers of naturally conceived twins compared to mothers who received fertility (MAR) treatments in both the Netherlands and Norway. The largest differences were observed for mothers who received hormonal ovulation induction, indicating maternal fertility issues. A higher PGS was also linked to shorter time to pregnancy. DZT showed significant negative genetic correlations with anovulatory infertility (r g = -0.698) and PCOS (r g = -0.278), and a positive genetic correlation with endometriosis (r g = 0.279). These findings suggest DZT PGS is an important, yet under-recognized fertility marker.
Open AccessPolygenic Scores for Dizygotic Twinning: Insights into the Genetic Architecture of Female Fertility
Natural dizygotic twinning (DZT) results from hyper-ovulation and is considered an indicator of female fertility. DZT has low polygenicity, with only 0.20% of SNPs estimated to have a nonzero effect. A polygenic score (PGS) for DZT explains 1.6% of variance in DZT liability and we observe an odds ratio of 2.29 between the 1 st and the 10 th PGS decile. The PGS is higher in mothers of naturally conceived twins compared to mothers who received fertility (MAR) treatments in both the Netherlands and Norway. The largest differences were observed for mothers who received hormonal ovulation induction, indicating maternal fertility issues. A higher PGS was also linked to shorter time to pregnancy. DZT showed significant negative genetic correlations with anovulatory infertility (r g = -0.698) and PCOS (r g = -0.278), and a positive genetic correlation with endometriosis (r g = 0.279). These findings suggest DZT PGS is an important, yet under-recognized fertility marker.
- Open Access
- 27 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (21) , 11551
Genome Sequencing Identifies 13 Novel Candidate Risk Genes for Autism Spectrum Disorder in a Qatari Cohort
Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by deficits in social communication, restricted interests, and repetitive behaviors. Despite considerable research efforts, the genetic complexity of ASD remains poorly understood, complicating diagnosis and treatment, especially in the Arab population, with its genetic diversity linked to migration, tribal structures, and high consanguinity. To address the scarcity of ASD genetic data in the Middle East, we conducted genome sequencing (GS) on 50 ASD subjects and their unaffected parents. Our analysis revealed 37 single-nucleotide variants from 36 candidate genes and over 200 CGG repeats in the FMR1 gene in one subject. The identified variants were classified as uncertain, likely pathogenic, or pathogenic based on in-silico algorithms and ACMG criteria. Notably, 52% of the identified variants were homozygous, indicating a recessive genetic architecture to ASD in this population. This finding underscores the significant impact of high consanguinity within the Qatari population, which could be utilized in genetic counseling/screening program in Qatar. We also discovered single nucleotide variants in 13 novel genes not previously associated with ASD: ARSF, BAHD1, CHST7, CUL2, FRMPD3, KCNC4, LFNG, RGS4, RNF133, SCRN2, SLC12A8, USP24, and ZNF746. Our investigation categorized the candidate genes into seven groups, highlighting their roles in cognitive development, including the ubiquitin pathway, transcription factors, solute carriers, kinases, glutamate receptors, chromatin remodelers, and ion channels.
- 27 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (21) , 11551
Open AccessGenome Sequencing Identifies 13 Novel Candidate Risk Genes for Autism Spectrum Disorder in a Qatari Cohort
Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by deficits in social communication, restricted interests, and repetitive behaviors. Despite considerable research efforts, the genetic complexity of ASD remains poorly understood, complicating diagnosis and treatment, especially in the Arab population, with its genetic diversity linked to migration, tribal structures, and high consanguinity. To address the scarcity of ASD genetic data in the Middle East, we conducted genome sequencing (GS) on 50 ASD subjects and their unaffected parents. Our analysis revealed 37 single-nucleotide variants from 36 candidate genes and over 200 CGG repeats in the FMR1 gene in one subject. The identified variants were classified as uncertain, likely pathogenic, or pathogenic based on in-silico algorithms and ACMG criteria. Notably, 52% of the identified variants were homozygous, indicating a recessive genetic architecture to ASD in this population. This finding underscores the significant impact of high consanguinity within the Qatari population, which could be utilized in genetic counseling/screening program in Qatar. We also discovered single nucleotide variants in 13 novel genes not previously associated with ASD: ARSF, BAHD1, CHST7, CUL2, FRMPD3, KCNC4, LFNG, RGS4, RNF133, SCRN2, SLC12A8, USP24, and ZNF746. Our investigation categorized the candidate genes into seven groups, highlighting their roles in cognitive development, including the ubiquitin pathway, transcription factors, solute carriers, kinases, glutamate receptors, chromatin remodelers, and ion channels.
- Open Access
Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery: a multi-ancestry study in 10 960 individuals from 9 biobanks
Obesity is a significant public health concern. GLP-1 receptor agonists (GLP1-RA), predominantly in use as a type 2 diabetes treatment, are a promising pharmacological approach for weight loss, while bariatric surgery (BS) remains a durable, but invasive, intervention. Despite observed heterogeneity in weight loss effects, the genetic effects on weight loss from GLP1-RA and BS have not been extensively explored in large sample sizes, and most studies have focused on differences in race and ethnicity, rather than genetic ancestry. We studied whether genetic factors, previously shown to affect body weight, impact weight loss due to GLP1-RA therapy or BS in 10,960 individuals from 9 multi-ancestry biobank studies in 6 countries. The average weight change between 6 and 12 months from therapy initiation was -3.93% for GLP1-RA users, with marginal differences across genetic ancestries. For BS patients the weight change between 6 and 48 months from the operation was -21.17%. There were no significant associations between weight loss due to GLP1-RA and polygenic scores for BMI or type 2 diabetes or specific missense variants in the GLP1R, PCSK1 and APOE genes, after multiple-testing correction. A higher polygenic score for BMI was significantly linked to lower weight loss after BS (+0.7% for 1 standard deviation change in the polygenic score, P = 1.24×10 -4 ), but the effect was modest and further reduced in sensitivity analyses. Our findings suggest that existing polygenic scores related to weight and type 2 diabetes and missense variants in the drug target gene do not have a large impact on GLP1-RA effectiveness. Our results also confirm the effectiveness of these treatments across all major continental ancestry groups considered.
Open AccessAssociation between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery: a multi-ancestry study in 10 960 individuals from 9 biobanks
Obesity is a significant public health concern. GLP-1 receptor agonists (GLP1-RA), predominantly in use as a type 2 diabetes treatment, are a promising pharmacological approach for weight loss, while bariatric surgery (BS) remains a durable, but invasive, intervention. Despite observed heterogeneity in weight loss effects, the genetic effects on weight loss from GLP1-RA and BS have not been extensively explored in large sample sizes, and most studies have focused on differences in race and ethnicity, rather than genetic ancestry. We studied whether genetic factors, previously shown to affect body weight, impact weight loss due to GLP1-RA therapy or BS in 10,960 individuals from 9 multi-ancestry biobank studies in 6 countries. The average weight change between 6 and 12 months from therapy initiation was -3.93% for GLP1-RA users, with marginal differences across genetic ancestries. For BS patients the weight change between 6 and 48 months from the operation was -21.17%. There were no significant associations between weight loss due to GLP1-RA and polygenic scores for BMI or type 2 diabetes or specific missense variants in the GLP1R, PCSK1 and APOE genes, after multiple-testing correction. A higher polygenic score for BMI was significantly linked to lower weight loss after BS (+0.7% for 1 standard deviation change in the polygenic score, P = 1.24×10 -4 ), but the effect was modest and further reduced in sensitivity analyses. Our findings suggest that existing polygenic scores related to weight and type 2 diabetes and missense variants in the drug target gene do not have a large impact on GLP1-RA effectiveness. Our results also confirm the effectiveness of these treatments across all major continental ancestry groups considered.